Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
Fabrizio Martora,1 Claudio Marasca,2 Sara Cacciapuoti,1 Federica Fariello,1 Luca Potestio,1 Teresa Battista,1 Massimiliano Scalvenzi,1 Matteo Megna1 1Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Dermatology Unit, Medical Depa...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-01-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/secukinumab-in-hidradenitis-suppurativa-patients-who-failed-adalimumab-peer-reviewed-fulltext-article-CCID |
| _version_ | 1827375929613090816 |
|---|---|
| author | Martora F Marasca C Cacciapuoti S Fariello F Potestio L Battista T Scalvenzi M Megna M |
| author_facet | Martora F Marasca C Cacciapuoti S Fariello F Potestio L Battista T Scalvenzi M Megna M |
| author_sort | Martora F |
| collection | DOAJ |
| description | Fabrizio Martora,1 Claudio Marasca,2 Sara Cacciapuoti,1 Federica Fariello,1 Luca Potestio,1 Teresa Battista,1 Massimiliano Scalvenzi,1 Matteo Megna1 1Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Dermatology Unit, Medical Department, “Antonio Cardarelli” National Hospital, Naples, ItalyCorrespondence: Fabrizio Martora, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Naples, 80131, Italy, Tel +39 - 081 – 7462457, Fax +39 - 081 – 7462442, Email fabriziomartora92@libero.itBackground: The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, the approval of this drug dates to 2015, data provided by real life show an effectiveness rate of about 60% percent. Recently (31 October 2023) FDA approves secukinumab for moderate-severe HS. The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes.Methods: We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting.Results: The initial cohort of patients recruited included 21 HS patients including 12 females and 9 males. About 57.1% of patients achieved the primary endpoint and recorded significant decrease in all the severity assessment scales (IHS4, DLQI and VAS pain scale) at week 16 and 52, when HiSCR reached 71.4%.Conclusion: The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon.Keywords: hidradenitis suppurativa, secukinumab, adalimumab, treatments |
| first_indexed | 2024-03-08T12:01:24Z |
| format | Article |
| id | doaj.art-32ff82cba8d64e4e9acbf042645f6fa1 |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-03-08T12:01:24Z |
| publishDate | 2024-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-32ff82cba8d64e4e9acbf042645f6fa12024-01-23T18:27:27ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152024-01-01Volume 1715916689898Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life StudyMartora FMarasca CCacciapuoti SFariello FPotestio LBattista TScalvenzi MMegna MFabrizio Martora,1 Claudio Marasca,2 Sara Cacciapuoti,1 Federica Fariello,1 Luca Potestio,1 Teresa Battista,1 Massimiliano Scalvenzi,1 Matteo Megna1 1Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Dermatology Unit, Medical Department, “Antonio Cardarelli” National Hospital, Naples, ItalyCorrespondence: Fabrizio Martora, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Naples, 80131, Italy, Tel +39 - 081 – 7462457, Fax +39 - 081 – 7462442, Email fabriziomartora92@libero.itBackground: The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, the approval of this drug dates to 2015, data provided by real life show an effectiveness rate of about 60% percent. Recently (31 October 2023) FDA approves secukinumab for moderate-severe HS. The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes.Methods: We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting.Results: The initial cohort of patients recruited included 21 HS patients including 12 females and 9 males. About 57.1% of patients achieved the primary endpoint and recorded significant decrease in all the severity assessment scales (IHS4, DLQI and VAS pain scale) at week 16 and 52, when HiSCR reached 71.4%.Conclusion: The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon.Keywords: hidradenitis suppurativa, secukinumab, adalimumab, treatmentshttps://www.dovepress.com/secukinumab-in-hidradenitis-suppurativa-patients-who-failed-adalimumab-peer-reviewed-fulltext-article-CCIDhidradenitis suppurativasecukinumabadalimumabtreatments |
| spellingShingle | Martora F Marasca C Cacciapuoti S Fariello F Potestio L Battista T Scalvenzi M Megna M Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study Clinical, Cosmetic and Investigational Dermatology hidradenitis suppurativa secukinumab adalimumab treatments |
| title | Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study |
| title_full | Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study |
| title_fullStr | Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study |
| title_full_unstemmed | Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study |
| title_short | Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study |
| title_sort | secukinumab in hidradenitis suppurativa patients who failed adalimumab a 52 week real life study |
| topic | hidradenitis suppurativa secukinumab adalimumab treatments |
| url | https://www.dovepress.com/secukinumab-in-hidradenitis-suppurativa-patients-who-failed-adalimumab-peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT martoraf secukinumabinhidradenitissuppurativapatientswhofailedadalimumaba52weekreallifestudy AT marascac secukinumabinhidradenitissuppurativapatientswhofailedadalimumaba52weekreallifestudy AT cacciapuotis secukinumabinhidradenitissuppurativapatientswhofailedadalimumaba52weekreallifestudy AT fariellof secukinumabinhidradenitissuppurativapatientswhofailedadalimumaba52weekreallifestudy AT potestiol secukinumabinhidradenitissuppurativapatientswhofailedadalimumaba52weekreallifestudy AT battistat secukinumabinhidradenitissuppurativapatientswhofailedadalimumaba52weekreallifestudy AT scalvenzim secukinumabinhidradenitissuppurativapatientswhofailedadalimumaba52weekreallifestudy AT megnam secukinumabinhidradenitissuppurativapatientswhofailedadalimumaba52weekreallifestudy |